Ziftomenib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ziftomenib
- DrugBank Accession Number
- DB17171
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 717.88
Monoisotopic: 717.285498465 - Chemical Formula
- C33H42F3N9O2S2
- Synonyms
- (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile
- 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)-
- Menin-mll interaction inhibitor ko 539
- External IDs
- KO 539
- KO-539
- KO539
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4MOD1F4ENC
- CAS number
- 2134675-36-6
- InChI Key
- BGGALFIXXQOTPY-NRFANRHFSA-N
- InChI
- InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1
- IUPAC Name
- 1-[(2S)-2-(4-methanesulfonylpiperazin-1-yl)propyl]-4-methyl-5-[(4-{[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile
- SMILES
- CNC1=NC(NC2CCN(CC3=CC=C4N(C[C@H](C)N5CCN(CC5)S(C)(=O)=O)C(=CC4=C3C)C#N)CC2)=C2C=C(CC(F)(F)F)SC2=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 115009296
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Not Yet Recruiting Treatment Relapsed/Refractory KMT2A-r Acute Leukemia / Relapsed/Refractory NPM1-m Acute Leukemia / Relapsed/Refractory NUP98-r Acute Leukemia 1 1 Recruiting Treatment Acute Leukemia / Acute Myeloid Leukemia / AML With Mutated NPM1 / Hematological Malignancy / KMT2Ar / Leukemias / MLL Rearrangement / Myeloid Leukemias / Neoplasms by Histologic Type / NPM1 Mutation 1 1 Recruiting Treatment Acute Myeloid Leukemia / AML With Mutated NPM1 / Granulocytic Sarcoma / KMT2Ar / Mixed Lineage Leukemia Gene Mutation / Mixed Phenotype Acute Leukemia (MPAL) / NPM1 Mutation / Recurrent Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia (AML) / Relapsed Acute Myelogenous Leukemia (AML) 1 1, 2 Recruiting Treatment Acute Leukemia of Ambiguous Lineage / Acute Myeloid Leukemia / Advanced Malignant Neoplasm / Mixed Lineage Leukemia / Mixed Phenotype Acute Leukemia (MPAL) 1 1, 2 Recruiting Treatment Lymphoblastic Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0232 mg/mL ALOGPS logP 4.56 ALOGPS logP 4.16 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 16.46 Chemaxon pKa (Strongest Basic) 8.76 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 122.42 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 189.92 m3·mol-1 Chemaxon Polarizability 75.13 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 23, 2022 23:24 / Updated at December 01, 2022 11:36